Cargando…

Rituximab as a novel treatment for heart failure: evidence from a case series

Detalles Bibliográficos
Autores principales:	Aimo, Alberto, Tavoni, Antonio, Buda, Gabriele, Emdin, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939812/ https://www.ncbi.nlm.nih.gov/pubmed/31911994 http://dx.doi.org/10.1093/ehjcr/ytz227

Ejemplares similares

Building medical knowledge from real world registries: The case of heart failure
por: Aimo, Alberto, et al.
Publicado: (2018)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Prognostic Value of sST2 in Heart Failure
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block
por: Aimo, Alberto, et al.
Publicado: (2021)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)

Novel Drug Targets for Central Apneas in Heart Failure: On the Road
por: Borrelli, Chiara, et al.
Publicado: (2021)

Intracoronary Delivery of Mitochondria to Prevent Ischemia–Reperfusion Injury: Challenging Pathway From Bench to Bedside
por: Aimo, Alberto, et al.
Publicado: (2020)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure
por: Aspromonte, Nadia, et al.
Publicado: (2017)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
por: Chianca, Michela, et al.
Publicado: (2022)

Novel Therapies for Heart Failure
Publicado: (2015)

Heart failure epidemiology and novel treatments in Japan: facts and numbers
por: Konishi, Masaaki, et al.
Publicado: (2016)

Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction: Similarities and Differences
por: Saccaro, Luigi F., et al.
Publicado: (2021)

Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter?
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Rituximab in idiopathic nephrotic syndrome: still waiting for stronger evidences
por: Belangero, Vera Maria Santoro
Publicado: (2023)

Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure
por: Mirizzi, Gianluca, et al.
Publicado: (2016)

Novel Device Therapies for Heart Failure
por: Alkhatib, Deya, et al.
Publicado: (2023)

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
por: Morfino, Paolo, et al.
Publicado: (2022)

Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus
por: Cai, Xiao-Ling, et al.
Publicado: (2020)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Atrial amyloidosis: mechanisms and clinical manifestations
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

Safety and Efficacy of Amiodarone in a Patient With COVID-19
por: Castaldo, Nadia, et al.
Publicado: (2020)

Multiple hormone deficiency syndrome: a novel topic in chronic heart failure
por: Salzano, Andrea, et al.
Publicado: (2018)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

The treatment of heart failure: an ideal challenge for the heart team
por: Reichenspurner, Hermann
Publicado: (2019)

Beta Blockers in Heart Failure: More Evidence for an Old Friend
por: Baek, Sang Hong
Publicado: (2018)

Surgical treatment concepts for heart failure
por: Delmo Walter, E M, et al.
Publicado: (2013)

Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

Novel Strategies Reflect the Paradigm Shift in the Treatment of Heart Failure with Reduced Ejection Fraction
por: Kida, Keisuke
Publicado: (2021)

Use of rituximab in glomerulopathies
por: Dias, Cristiane Bitencourt, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4ta1u1clsb8285aocrpaqr1qjt